Goodman Andrew D, Gyang Tirisham, Smith Andrew D
a Department of Neurology , University of Rochester Medical Center , Rochester , NY , USA.
Expert Opin Investig Drugs. 2016 Oct;25(10):1231-7. doi: 10.1080/13543784.2016.1221924. Epub 2016 Aug 22.
Multiple sclerosis (MS) is an autoimmune disorder of the central nervous system (CNS) characterized by inflammatory demyelination and progressive axonal loss. Clinically, this is manifest as relapsing and remitting neurological symptoms and progressive accumulation of disability. Ibudilast is a nonselective phosphodiesterase inhibitor which works by blocking the cleavage of cyclic adenosine monophosphate (cAMP). It has been found to have anti-inflammatory and neuroprotective properties in animal studies and in-vitro studies; it is currently being studied in progressive MS.
This article reviews various studies looking at ibudilast as a potential therapy for MS. It summarizes prior and current clinical trials of ibudilast in MS as well as its pharmacology.
Although ibudilast has not been found to decrease the focal inflammatory activity in relapsing MS, it was shown to have an effect on preserving brain volume and disability progression. Ibudilast may have a role in the treatment of progressive MS phenotypes.
多发性硬化症（MS）是一种中枢神经系统（CNS）的自身免疫性疾病，其特征为炎症性脱髓鞘和进行性轴突损失。临床上，这表现为复发-缓解型神经症状和残疾的逐渐累积。异丁司特是一种非选择性磷酸二酯酶抑制剂，通过阻断环磷酸腺苷（cAMP）的裂解起作用。在动物研究和体外研究中已发现它具有抗炎和神经保护特性；目前正在对其进行进行性MS方面的研究。
本文综述了各项将异丁司特视为MS潜在治疗方法的研究。总结了异丁司特在MS中的既往及当前临床试验及其药理学。
尽管未发现异丁司特能降低复发型MS中的局灶性炎症活性，但它显示出对保留脑容量和残疾进展有作用。异丁司特可能在进行性MS表型的治疗中发挥作用。
